PR domain-containing protein 15 (PRDM15)

PR domain-containing protein 15 (PRDM15) is a zinc finger transcription factor and putative methyltransferase that plays a pivotal role in embryonic stem cell pluripotency and early development[1][3][4][5][6]. It acts primarily by regulating transcriptional networks controlling the WNT and MAPK-ERK signaling pathways, essential for stem cell maintenance and cell fate specification[1][3][4][5]. PRDM15 can function as both a transcriptional activator and repressor, depending on context and cell type, and may have enzymatic activity for non-histone methylation—though this activity is not fully characterized[1][4]. Loss-of-function mutations in PRDM15 result in profound patterning defects and malformations such as holoprosencephaly, while overexpression drives metabolic pathways that support B-cell lymphomagenesis[3][4][7]. PRDM15 emerges as a promising cancer therapeutic target due to its limited expression in adult tissues and key regulatory function in tumor metabolism[3][4]. Note: No established small molecule inhibitors of PRDM15 are approved, though preclinical efforts including antisense oligonucleotides exist for cancer models[3][4]. Other PRDM family members (e.g., PRDM9) have inspired first-in-class inhibitor development[4].

Other names

C21orf83ZNF298PRDM15PFM15PR domain zinc finger protein 15Zinc finger protein 298

Drugs would act as inhibitors of transcriptional activity or as modulators of methyltransferase (if confirmed). Antisense oligonucleotides may induce exon skipping and protein downregulation, leading to cell death in lymphoma cells.